Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This study is looking to see whether the combination of Tucidinostat and nab-paclitaxel is
safe and effective in participants with advanced HR+/HER2- breast cancer.